



PB 10 of 2024

National Health (Minimum Stockholding) Amendment Determination (No. 1) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 30/01/2024

Nikolai Tsyganov
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name	1
2 Commencement.....	1
3 Authority	1
4 Schedules.....	1
Schedule 1—Amendments commencing 1 February 2024	2
<i>National Health (Minimum Stockholding) Determination 2023</i>	2
Schedule 2—Amendments commencing 1 June 2024	34
<i>National Health (Minimum Stockholding) Determination 2023</i>	34

1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 1) 2024*.
- (2) This instrument may also be cited as PB 10 of 2024.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 February 2024.	1 February 2024
2. Schedule 1	1 February 2024.	1 February 2024
3. Schedule 2	1 June 2024.	1 June 2024

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 February 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1

Omit:

Aciclovir	Tablet 200 mg	Oral	GenRx Aciclovir	between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand
Alendronic acid with colecalciferol	Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol	Oral	Fosamax Plus 70 mg/140 mcg	between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand
Alendronic acid with colecalciferol	Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol	Oral	Fosamax Plus	between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand

2 Schedule 1

Omit:

Allopurinol	Tablet 300 mg	Oral	Allopurinol APOTEX	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
-------------	---------------	------	-----------------------	----------------------------------------------------------------------------------------

3 Schedule 1

Omit:

Amisulpride	Tablet 100 mg	Oral	Amisulpride 100 Winthrop	Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand
Amitriptyline	Tablet containing amitriptyline hydrochloride 10 mg	Oral	APX-Amitriptyline	between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand

4 Schedule 1

Omit:

Amlodipine	Tablet 10 mg (as besilate)	Oral	Amlodipine Amneal	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Amlodipine	Tablet 5 mg (as besilate)	Oral	Amneal	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

5 Schedule 1

Omit:

Amoxicillin with clavulanic acid	Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	Oral	Amoxyclav AN 500/125	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Amoxicillin with clavulanic acid	Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	Oral	Amoxyclav AN 875/125	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

6 Schedule 1

After:

Aripiprazole	Tablet 10 mg	Oral	APO-Aripiprazole	3 months stock by reference to usual demand
--------------	--------------	------	------------------	---------------------------------------------

insert:

Aripiprazole	Tablet 10 mg	Oral	Aripic Aripiprazole	between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand
--------------	--------------	------	---------------------	--------------------------------------------------------------------------------------

7 Schedule 1

Omit:

Aripiprazole	Tablet 30 mg	Oral	Aripiprazole generichealth	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
--------------	--------------	------	----------------------------	-----------------------------------------------------------------------------------------

8 Schedule 1

Omit:

Atenolol	Tablet 50 mg	Oral	Atenolol Amneal	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
----------	--------------	------	-----------------	-----------------------------------------------------------------------------------------

9 Schedule 1

After:

Atomoxetine	Capsule 80 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
-------------	----------------------------------	------	-----------------	---------------------------------------------

insert:

Atorvastatin	Tablet 10 mg (as calcium)	Oral	Atorvastatin GH	between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand
--------------	---------------------------	------	-----------------	--------------------------------------------------------------------------------------

10 Schedule 1

After:

Atorvastatin	Tablet 20 mg (as calcium)	Oral	Atorvastatin GH	Between 1 October 2023 and 29 February 2024—0 months stock by reference to usual demand
--------------	---------------------------	------	-----------------	-----------------------------------------------------------------------------------------

insert:

Atorvastatin	Tablet 40 mg (as calcium)	Oral	Atorvastatin GH	between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand
--------------	---------------------------	------	-----------------	--------------------------------------------------------------------------------------

11 Schedule 1

Omit:

Azathioprine	Tablet 50 mg	Oral	Azathioprine GH	Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand
--------------	--------------	------	-----------------	----------------------------------------------------------------------------------------

12 Schedule 1

Omit:

Bleomycin	Powder for injection containing bleomycin sulfate 15,000 I.U.	Injection	CIPLA BLEOMYCIN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
-----------	---------------------------------------------------------------	-----------	--------------------	-----------------------------------------------------------------------------------------

13 Schedule 1

Omit:

Bosentan	Tablet 62.5 mg (as monohydrate)	Oral	Bosentan Cipla	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Calcitriol	Capsule 0.25 microgram	Oral	Calcitriol AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

14 Schedule 1

Omit:

Candesartan	Tablet containing candesartan cilexetil 4 mg	Oral	APO-Candesartan	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
Candesartan	Tablet containing candesartan cilexetil 4 mg	Oral	CANDESAN	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
Candesartan	Tablet containing candesartan cilexetil 8 mg	Oral	APO-Candesartan	between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand
Candesartan	Tablet containing candesartan cilexetil 8 mg	Oral	CANDESAN	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand

15 Schedule 1

After:

Calcium	Tablet, chewable, 500 mg (as carbonate)	Oral	Cal-500	after 30 November 2023—6 months stock by reference to usual PBS demand
insert:				
Capecitabine	Tablet 150 mg	Oral	Capecitabine-DRLA	between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand

16 Schedule 1

Omit:

Cefaclor	Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL	Oral	APO-Cefaclor	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Cefaclor	Tablet (sustained release) 375 mg (as monohydrate)	Oral	APO-Cefaclor CD	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Cefalexin	Capsule 500 mg (as monohydrate)	Oral	APO-Cephalexin	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
Cefazolin	Powder for injection 2 g (as sodium)	Injection	Cefazolin-AFT	between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand
Cefepime	Powder for injection 1 g (as hydrochloride)	Injection	Cefepime Alphapharm	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Cefepime	Powder for injection 1 g (as hydrochloride)	Injection	Cefepime-AFT	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Cefepime	Powder for injection 2 g (as hydrochloride)	Injection	Cefepime Alphapharm	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ceftriaxone	Powder for injection 1 g (as sodium)	Injection	Ceftriaxone-AFT	between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand
Ceftriaxone	Powder for injection 2 g (as sodium)	Injection	Ceftriaxone-AFT	between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand

17 Schedule 1

After:

Carmellose with glycerin	Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL	Application to the Eye	Optive	4 months stock by reference to usual PBS demand
--------------------------	------------------------------------------------------------------------------	------------------------	--------	-------------------------------------------------

insert:

Ceftriaxone	Powder for injection 2 g (as sodium)	Injection	Ceftriaxone Viartis	after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viartis and Ceftriaxone Alphapharm added together
-------------	--------------------------------------	-----------	---------------------	-------------------------------------------------------------------------------------------------------------------------------------

18 Schedule 1

Omit:

Citalopram	Tablet 10 mg (as hydrobromide)	Oral	Citalopram AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Citalopram	Tablet 20 mg (as hydrobromide)	Oral	Citalopram AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Citalopram	Tablet 40 mg (as hydrobromide)	Oral	Citalopram AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

19 Schedule 1

Omit:

Clarithromycin	Tablet 250 mg	Oral	Clarithromycin AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
----------------	---------------	------	-------------------	-----------------------------------------------------------------------------------------

20 Schedule 1

Omit:

Cyproterone	Tablet containing cyproterone acetate 100 mg	Oral	APO-Cyproterone	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Cyproterone	Tablet containing cyproterone acetate 100 mg	Oral	Cyprone 100	between 1 December 2023 and 31 January 2024—0 months

				stock by reference to usual demand
Cyproterone	Tablet containing cyproterone acetate 100 mg	Oral	GenRx Cyproterone Acetate	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Cyproterone	Tablet containing cyproterone acetate 50 mg	Oral	APO-Cyproterone	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Cyproterone	Tablet containing cyproterone acetate 50 mg	Oral	Cyprone 50	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Cyproterone	Tablet containing cyproterone acetate 50 mg	Oral	GenRx Cyproterone Acetate	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

21 Schedule 1

Omit:

Desvenlafaxine	Tablet (modified release) 100 mg	Oral	Desvenlafaxine Actavis	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Desvenlafaxine	Tablet (modified release) 50 mg	Oral	Desvenlafaxine Actavis	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Dexamethasone with framycetin and gramicidin	Ear drops containing dexamethasone 500 micrograms (as sodium metasulfobenzoate), framycetin sulfate 5 mg and gramicidin 50 micrograms per mL, 8 mL	Application to the Ear	Sofradex	between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand

22 Schedule 1

Omit:

Diclofenac	Tablet (enteric coated) containing diclofenac sodium 25 mg	Oral	Diclofenac AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
------------	------------------------------------------------------------	------	---------------	-----------------------------------------------------------------------------------------

23 Schedule 1

Omit:

Diclofenac	Tablet (enteric coated) containing diclofenac sodium 50 mg	Oral	Diclofenac AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
------------	------------------------------------------------------------	------	---------------	-----------------------------------------------------------------------------------------

24 Schedule 1

After:

Domperidone	Tablet 10 mg	Oral	Motilium	between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand
-------------	--------------	------	----------	---------------------------------------------------------------------------------------

insert:

Dosulepin	Capsule containing dosulepin hydrochloride 25 mg	Oral	Dosulepin Viatris	after 31 May 2024—6 months stock by reference to usual demand of both Dosulepin Viatris and Dosulepin Mylan added together
-----------	--------------------------------------------------	------	-------------------	----------------------------------------------------------------------------------------------------------------------------

25 Schedule 1

Omit:

Doxycycline	Tablet 100 mg (as hyclate)	Oral	Doxsig	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
Doxycycline	Tablet 100 mg (as monohydrate)	Oral	APO-Doxycycline	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Doxycycline	Tablet 50 mg (as hyclate)	Oral	APX-Doxycycline	between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand

26 Schedule 1

Omit:

Doxycycline	Tablet 50 mg (as monohydrate)	Oral	APO-Doxycycline	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
-------------	-------------------------------	------	-----------------	------------------------------------------------------------------------------------------

27 Schedule 1

After:				
Enalapril	Tablet containing enalapril maleate 10 mg	Oral	APO-Enalapril	4 months stock by reference to usual demand
insert:				
Enalapril	Tablet containing enalapril maleate 10 mg	Oral	Enalapril generichealth	between 1 February 2024 and 31 May 2024—0 months stock by reference to usual demand

28 Schedule 1

After:				
Enalapril	Tablet containing enalapril maleate 5 mg	Oral	APO-Enalapril	4 months stock by reference to usual demand
insert:				
Enalapril	Tablet containing enalapril maleate 5 mg	Oral	Enalapril generichealth	between 1 February 2024 and 31 May 2024—0 months stock by reference to usual demand

29 Schedule 1

Omit:				
Esomeprazole	Capsule (enteric) 20 mg (as magnesium)	Oral	Noxicid Caps	between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand
Esomeprazole	Capsule (enteric) 40 mg (as magnesium)	Oral	Noxicid Caps	between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand
Esomeprazole	Tablet (enteric coated) 20 mg (as magnesium trihydrate)	Oral	Esomeprazole Apotex	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Esomeprazole	Tablet (enteric coated) 40 mg (as magnesium trihydrate)	Oral	Esomeprazole Apotex	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

30 Schedule 1

Omit:

Ezetimibe with simvastatin	Tablet 10 mg-10 mg	Oral	EZEVYT 10/10	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-10 mg	Oral	Vytorin	between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-10 mg	Oral	Zeklen 10/10 mg	between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand

31 Schedule 1

Omit:

Ezetimibe with simvastatin	Tablet 10 mg-20 mg	Oral	EZEVYT 10/20	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-20 mg	Oral	Vytorin	between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-20 mg	Oral	Zeklen 10/20 mg	between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand

32 Schedule 1

Omit:

Ezetimibe with simvastatin	Tablet 10 mg-40 mg	Oral	EZEVYT 10/40	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-40 mg	Oral	Vytorin	between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-40 mg	Oral	Zeklen 10/40 mg	between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand

33 Schedule 1

Omit:

Ezetimibe with simvastatin	Tablet 10 mg-80 mg	Oral	EZEVYT 10/80	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-80 mg	Oral	Vytorin	between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg-80 mg	Oral	Zeklen 10/80 mg	between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand
Famciclovir	Tablet 125 mg	Oral	Famciclovir-GA	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Famciclovir	Tablet 250 mg	Oral	Famciclovir-GA	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Famciclovir	Tablet 500 mg	Oral	Famciclovir-GA	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

34 Schedule 1

Omit:

Flucloxacillin	Capsule 250 mg (as sodium monohydrate)	Oral	APO-Flucloxacillin	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
----------------	----------------------------------------	------	--------------------	------------------------------------------------------------------------------------------

35 Schedule 1

Omit:

Fluorometholone	Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL	Application to the Eye	Flarex	4 months stock by reference to usual PBS demand
-----------------	----------------------------------------------------------------	------------------------	--------	-------------------------------------------------

substitute:

Fluorometholone	Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL	Application to the Eye	Flarex	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual PBS demand
-----------------	----------------------------------------------------------------	------------------------	--------	------------------------------------------------------------------------------------------

36 Schedule 1

Omit:

Furosemide	Tablet 20 mg	Oral	FUROSEMIDE AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Furosemide	Tablet 20 mg	Oral	Urex-M	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Furosemide	Tablet 40 mg	Oral	FUROSEMIDE AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Furosemide	Tablet 40 mg	Oral	Urex	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Gabapentin	Capsule 100 mg	Oral	Gabapentin APOTEX	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Gabapentin	Capsule 100 mg	Oral	GAPENTIN	between 1 July 2023 and 31 December 2023—3.5 months stock by reference to usual demand
Gabapentin	Capsule 300 mg	Oral	Gabapentin APOTEX	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Gabapentin	Capsule 300 mg	Oral	GAPENTIN	between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand
Gabapentin	Capsule 400 mg	Oral	Gabapentin APOTEX	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

37 Schedule 1

Omit:

Gabapentin	Tablet 600 mg	Oral	Gabapentin AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
------------	---------------	------	---------------	-----------------------------------------------------------------------------------------

38 Schedule 1

Omit:

Gemfibrozil	Tablet 600 mg	Oral	Lipigem	between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand
-------------	---------------	------	---------	--------------------------------------------------------------------------------------

39 Schedule 1

Omit:

Glimepiride	Tablet 2 mg	Oral	Amaryl	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
-------------	-------------	------	--------	-----------------------------------------------------------------------------------------

40 Schedule 1

Omit:

Glimepiride	Tablet 3 mg	Oral	Amaryl	Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand
-------------	-------------	------	--------	-----------------------------------------------------------------------------------------

41 Schedule 1

Omit:

Ibuprofen	Tablet 400 mg	Oral	APO-Ibuprofen 400	between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand
-----------	---------------	------	-------------------	--------------------------------------------------------------------------------------

42 Schedule 1

Omit:

Ipratropium	Nebuliser solution containing ipratropium bromide 250 micrograms (as monohydrate) in 1 mL single dose units, 30	Inhalation	APO-Ipratropium	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Ipratropium	Nebuliser solution containing ipratropium bromide 500 micrograms (as	Inhalation	APO-Ipratropium	between 1 November 2023 and 31 December 2023—0 months stock by

	monohydrate) in 1 mL single dose units, 30			reference to usual demand
Irbesartan with hydrochlorothiazide	Tablet 300 mg-25 mg	Oral	AVSARTAN HCT 300/25	between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand
Irbesartan	Tablet 300 mg	Oral	Irbesartan AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Irbesartan	Tablet 75 mg	Oral	Irbesartan AMNEAL	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Irbesartan	Tablet 75 mg	Oral	Irbesartan AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Irinotecan	I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL	Injection	MEDITAB IRINOTECAN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Irinotecan	I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL	Injection	MEDITAB IRINOTECAN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Isosorbide mononitrate	Tablet 60 mg (sustained release)	Oral	Isosorbide AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Isosorbide mononitrate	Tablet 60 mg (sustained release)	Oral	Monodur 60 mg	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Isotretinoin	Capsule 10 mg	Oral	Rocta 10	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Isotretinoin	Capsule 20 mg	Oral	Rocta 20	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Lamotrigine	Tablet 100 mg	Oral	APO-Lamotrigine	between 1 November 2023 and 31 December 2023—

				0 months stock by reference to usual demand
Lamotrigine	Tablet 200 mg	Oral	APO-Lamotrigine	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Lamotrigine	Tablet 25 mg	Oral	APO-Lamotrigine	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Lamotrigine	Tablet 50 mg	Oral	APO-Lamotrigine	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

43 Schedule 1

After:

Insect allergen extract-yellow jacket venom	Injection set containing 550 micrograms with diluent	Injection	Hymenoptera Yellow Jacket Venom	after 30 November 2023—6 months stock by reference to usual PBS demand
---------------------------------------------	------------------------------------------------------	-----------	---------------------------------	------------------------------------------------------------------------

insert:

Lamivudine with zidovudine	Tablet 150 mg-300 mg	Oral	Lamivudine/Zidovudine Viatris 150/300	after 31 May 2024—4 months stock by reference to usual demand of both Lamivudine/Zidovudine Viatris 150/300 and Lamivudine 150 mg + Zidovudine 300 mg Alphapharm added together
----------------------------	----------------------	------	---------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

44 Schedule 1

Omit:

Levonorgestrel with ethinylestradiol	Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets	Oral	Monofeme 28	Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand
Levonorgestrel with ethinylestradiol	Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets	Oral	Lenest 30 ED	between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand

45 Schedule 1

Omit:

Meloxicam	Capsule 15 mg	Oral	Chem mart Meloxicam	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Meloxicam	Capsule 15 mg	Oral	Terry White Chemists Meloxicam	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Meloxicam	Capsule 7.5 mg	Oral	Chem mart Meloxicam	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Meloxicam	Capsule 7.5 mg	Oral	Terry White Chemists Meloxicam	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Meloxicam	Tablet 7.5 mg	Oral	APX-Meloxicam	between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand

46 Schedule 1

Omit:

Metformin	Tablet (extended release) containing metformin hydrochloride 500 mg	Oral	Metformin XR 500 APOTEX	between 1 November 2023 and 31 December 2023— 0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 1 g	Oral	APO-Metformin 1000	between 1 November 2023 and 31 December 2023— 0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 1 g	Oral	Metformin AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 500 mg	Oral	APO-Metformin 500	between 1 November 2023 and 31 December 2023— 0 months stock by reference to usual demand
Metformin	Tablet containing metformin	Oral	Metformin AN	between 1 December 2023 and 31 January 2024—0 months

	hydrochloride 500 mg			stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 850 mg	Oral	APO-Metformin 850	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 850 mg	Oral	Chem mart Metformin	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 850 mg	Oral	Metformin AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 850 mg	Oral	Terry White Chemists Metformin	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Methotrexate	Solution concentrate for I.V. infusion 1000 mg in 10 mL vial	Injection	Pfizer Australia Pty Ltd	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

47 Schedule 1

After:

Methoxyflurane	Liquid for inhalation 999 mg per g, 3 ml (with inhaler)	Inhalation by mouth	Pentrox	6 months stock by reference to usual PBS demand
insert:				
Methylprednisolone	Powder for injection 40 mg (as sodium succinate)	Injection	Methylpred	between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand

48 Schedule 1

Omit:

Metoclopramide	Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL	Injection	Maxolon	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
----------------	----------------------------------------------------------------------------------	-----------	---------	-----------------------------------------------------------------------------------------

49 Schedule 1

Omit:

Mirtazapine	Tablet 15 mg (orally disintegrating)	Oral	Mirtazapine AN ODT	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Mirtazapine	Tablet 15 mg	Oral	APO-Mirtazapine	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Mirtazapine	Tablet 30 mg (orally disintegrating)	Oral	Mirtazapine AN ODT	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Mirtazapine	Tablet 30 mg	Oral	APO-Mirtazapine	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Mirtazapine	Tablet 30 mg	Oral	Mirtazon	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Mirtazapine	Tablet 45 mg (orally disintegrating)	Oral	Mirtazapine AN ODT	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Mirtazapine	Tablet 45 mg	Oral	APO-Mirtazapine	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Mirtazapine	Tablet 45 mg	Oral	Mirtazon	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

50 Schedule 1

Omit:

Moclobemide	Tablet 150 mg	Oral	APO-Moclobemide	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Moclobemide	Tablet 150 mg	Oral	Moclobemide AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Moclobemide	Tablet 300 mg	Oral	APO-Moclobemide	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Moclobemide	Tablet 300 mg	Oral	Moclobemide AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

51 Schedule 1

After:

Moxonidine	Tablet 200 micrograms	Oral	Moxonidine Viatris	4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together
insert:				
Moxonidine	Tablet 400 micrograms	Oral	Moxonidine Viatris	4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together
Mycophenolic acid	Capsule containing mycophenolate mofetil 250 mg	Oral	CellCept	between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand
Mycophenolic acid	Tablet containing mycophenolate mofetil 500 mg	Oral	CellCept	between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand

52 Schedule 1

Omit:

Olanzapine	Tablet 10 mg (orally disintegrating)	Oral	APO-Olanzapine ODT	between 1 July 2023 and 31 December 2023—3.5 months stock by reference to usual demand
Olanzapine	Tablet 15 mg (orally disintegrating)	Oral	APO-Olanzapine ODT	between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand

53 Schedule 1

After:

Norfloxacin	Tablet 400 mg	Oral	APO-Norfloxacin	2.5 months stock by reference to usual demand
insert:				
Olanzapine	Tablet 10 mg (orally disintegrating)	Oral	Zypine ODT	(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 10 mg (orally disintegrating), Oral, added together

54 Schedule 1

After:				
Olanzapine	Tablet 15 mg (orally disintegrating)	Oral	PRYZEX ODT	<p>(a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand</p> <p>(b) after 31 December 2023—3.5 months stock by reference to usual demand</p>
insert:				
Olanzapine	Tablet 15 mg (orally disintegrating)	Oral	Zypine ODT	<p>(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral;</p> <p>(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 15 mg (orally disintegrating), Oral, added together.</p>
Olanzapine	Tablet 20 mg (orally disintegrating)	Oral	Zypine ODT	<p>(a) between 1 February 2024 and 30 September 2024—4 months stock by</p>

reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral;

(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 20 mg (orally disintegrating), Oral, added together

55 Schedule 1

Omit:

Olanzapine	Tablet 5 mg (orally disintegrating)	Oral	Olanzapine ODT generichealth 5	Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand
------------	-------------------------------------	------	--------------------------------	-----------------------------------------------------------------------------------------

56 Schedule 1

After:

Olanzapine	Tablet 5 mg (orally disintegrating)	Oral	APO-Olanzapine ODT	3 months stock by reference to usual demand
------------	-------------------------------------	------	--------------------	---------------------------------------------

insert:

Olanzapine	Tablet 5 mg (orally disintegrating)	Oral	Zypine ODT	(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical
------------	-------------------------------------	------	------------	---------------------------------------------------------------------------------------------------------------------------------------------

item Olanzapine, Wafer 5 mg, Oral;
(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 5 mg (orally disintegrating), Oral, added together

57 Schedule 1

Omit:

Olmesartan with hydrochlorothiazide	Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg	Oral	APX-Olmesartan/HC TZ	between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand
-------------------------------------	-------------------------------------------------------------------------------	------	----------------------	--------------------------------------------------------------------------------------

58 Schedule 1

Omit:

Ondansetron	Tablet (orally disintegrating) 4 mg	Oral	APO-Ondansetron ODT	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Ondansetron	Tablet (orally disintegrating) 4 mg	Oral	Ondansetron AN ODT	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ondansetron	Tablet (orally disintegrating) 8 mg	Oral	APO-Ondansetron ODT	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Ondansetron	Tablet (orally disintegrating) 8 mg	Oral	Ondansetron AN ODT	between 1 December 2023 and 31 January 2024—0 months

				stock by reference to usual demand
Ondansetron	Tablet 4 mg (as hydrochloride dihydrate)	Oral	Ondansetron AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ondansetron	Tablet 4 mg (as hydrochloride dihydrate)	Oral	Ondansetron APOTEX	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Ondansetron	Tablet 8 mg (as hydrochloride dihydrate)	Oral	Ondansetron AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ondansetron	Tablet 8 mg (as hydrochloride dihydrate)	Oral	Ondansetron APOTEX	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

59 Schedule 1

After:

Oxycodone	Oral solution containing oxycodone hydrochloride 1 mg per mL, 1 mL	Oral	OxyNorm Liquid 1mg/mL	4 months stock by reference to usual PBS demand
-----------	--------------------------------------------------------------------	------	-----------------------	-------------------------------------------------

insert:

Oxycodone	Tablet containing oxycodone hydrochloride 5 mg	Oral	Oxycodone Viatris	after 28 February 2024—6 months stock by reference to usual demand of both Oxycodone Viatris and Oxycodone Mylan added together
-----------	------------------------------------------------	------	-------------------	---------------------------------------------------------------------------------------------------------------------------------

60 Schedule 1

Omit:

Pantoprazole	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	Oral	Pantoprazole APOTEX	between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand
Pantoprazole	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	Oral	Sozol	between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand

Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	Oral	Pantoprazole AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	Oral	Pantoprazole APOTEX	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand

61 Schedule 1

After:

Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	Oral	Sozol	(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand
--------------	---------------------------------------------------------	------	-------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------

insert:

Paraffin with retinol palmitate	Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinol palmitate, 5 g	Application to the Eye	VitA-POS	between 1 April 2024 and 30 September 2024—0 months stock by reference to usual demand
---------------------------------	-------------------------------------------------------------------------------------------------------------------------------------	------------------------	----------	----------------------------------------------------------------------------------------

62 Schedule 1

Omit:

Paroxetine	Tablet 20 mg (as hydrochloride)	Oral	Paroxetine AN	Between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Pegfilgrastim	Injection 6 mg in 0.6 mL single use pre-filled syringe	Injection	Ristempa	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

63 Schedule 1

Omit:

Perindopril	Tablet containing perindopril erbumine 4 mg	Oral	Perindopril generichealth	Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand
Perindopril	Tablet containing perindopril erbumine 8 mg	Oral	Perindopril generichealth	Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand
Perindopril with amlodipine	Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate)	Oral	APO-Perindopril Arginine/Amlodipine 5/10	between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand

64 Schedule 1

Omit:

Pravastatin	Tablet containing pravastatin sodium 10 mg	Oral	APO-Pravastatin	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Pravastatin	Tablet containing pravastatin sodium 20 mg	Oral	APO-Pravastatin	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Pravastatin	Tablet containing pravastatin sodium 40 mg	Oral	APO-Pravastatin	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Pravastatin	Tablet containing pravastatin sodium 80 mg	Oral	APO-Pravastatin	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

65 Schedule 1

Omit:

Pregabalin	Capsule 25 mg	Oral	LYPRALIN	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
------------	---------------	------	----------	------------------------------------------------------------------------------------------

66 Schedule 1

Omit:

Pregabalin	Capsule 300 mg	Oral	LYPRALIN	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
------------	----------------	------	----------	------------------------------------------------------------------------------------------

67 Schedule 1

After:

Probenecid	Tablet 500 mg	Oral	Pro-Cid	after 30 November 2023—6 months stock by reference to usual PBS demand
------------	---------------	------	---------	------------------------------------------------------------------------

insert:

Prochlorperazine	Tablet containing prochlorperazine maleate 5 mg	Oral	Stemzine	between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand
------------------	-------------------------------------------------	------	----------	---------------------------------------------------------------------------------------

68 Schedule 1

Omit:

Quetiapine	Tablet 100 mg (as fumarate)	Oral	Quetiapine AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Quetiapine	Tablet 300 mg (as fumarate)	Oral	Quetiapine AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

69 Schedule 1

Omit:

Rabeprazole	Tablet containing rabeprazole sodium 20 mg (enteric coated)	Oral	APO-Rabeprazole	between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand
Raloxifene	Tablet containing raloxifene hydrochloride 60 mg	Oral	APO-Raloxifene	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

70 Schedule 1

Omit:

Ramipril	Tablet 2.5 mg	Oral	APO-Ramipril	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
Ramipril	Tablet 5 mg	Oral	Prilace	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand

71 Schedule 1

Omit:

Ramipril	Capsule 1.25 mg	Oral	APO-Ramipril	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
----------	-----------------	------	--------------	-----------------------------------------------------------------------------------------

72 Schedule 1

Omit:

Risperidone	Tablet 1 mg	Oral	APO-Risperidone	between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand
-------------	-------------	------	-----------------	--------------------------------------------------------------------------------------

73 Schedule 1

Omit:

Risperidone	Tablet 4 mg	Oral	Rispa	between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand
Rizatriptan	Tablet (orally disintegrating) 10 mg (as benzoate)	Oral	Rizatriptan AN ODT	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Rosuvastatin	Tablet 10 mg (as calcium)	Oral	APX-Rosuvastatin	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
Rosuvastatin	Tablet 5 mg (as calcium)	Oral	APX-Rosuvastatin	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
Rosuvastatin	Tablet 5 mg (as calcium)	Oral	Crosuva 5	between 1 July 2023 and 31 December 2023—5.5 months

					stock by reference to usual demand
74 Schedule 1					
After:					
Risperidone	Tablet 3 mg	Oral	Risperidone generichealth		between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand
insert:					
Risperidone	Tablet 4 mg	Oral	Risperidone generichealth		between 1 February 2024 and 30 April 2024—0 months stock by reference to usual demand
75 Schedule 1					
Omit:					
Salbutamol	Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30	Inhalation	Salbutamol AN		between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
76 Schedule 1					
Omit:					
Sertraline	Tablet 100 mg (as hydrochloride)	Oral	Sertraline AN		between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Sertraline	Tablet 50 mg (as hydrochloride)	Oral	Sertraline AN		between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Sildenafil	Tablet 20 mg (as citrate)	Oral	Sildenafil AN PHT 20		between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
77 Schedule 1					
Omit:					
Sotalol	Tablet containing sotalol hydrochloride 160 mg	Oral	APO-Sotalol		between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

78 Schedule 1

Omit:

Sotalol	Tablet containing sotalol hydrochloride 80 mg	Oral	APO-Sotalol	between 1 November 2023 and 31 December 2023— 0 months stock by reference to usual demand
---------	-----------------------------------------------------	------	-------------	----------------------------------------------------------------------------------------------------------

79 Schedule 1

Omit:

Tacrolimus	Capsule 0.5 mg	Oral	Tacrograf	between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand
------------	----------------	------	-----------	--------------------------------------------------------------------------------------------------

80 Schedule 1

Omit:

Temozolomide	Capsule 180 mg	Oral	Temodal	between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand
Temozolomide	Capsule 250 mg	Oral	Temodal	between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand

81 Schedule 1

After:

Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	Oral	Tenofovir/Emtricitabine 300/200 APOTEX	3 months stock by reference to usual demand
---------------------------------	----------------------------------------------------------------------------------------------	------	-------------------------------------------	---------------------------------------------------

insert:

Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg	Oral	Tenofovir Disoproxil Emtricitabine Viartis 300/200	after 30 April 2024— 4 months stock by reference to usual demand of both Tenofovir Disoproxil Emtricitabine Viartis 300/200 and Tenofovir Disoproxil Emtricitabine Mylan 300/200 added together
---------------------------------	------------------------------------------------------------------------------------------	------	----------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

82 Schedule 1

Triglycerides, medium chain	After: Oral liquid 225 mL, 15 (K.Quik)	Oral	K.Quik	0 months stock by reference to usual PBS demand
Trimethoprim	insert: Tablet 300 mg	Oral	Trimethoprim Viatris	after 30 April 2024— 6 months stock by reference to usual demand of both Trimethoprim Viatris and Trimethoprim Mylan added together
Tropisetron	I.V. injection 5 mg (as hydrochloride) in 5 mL	Injection	Tropisetron-AFT	between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand

83 Schedule 1

Voriconazole	After: Powder for oral suspension 40 mg per mL, 70 mL	Oral	Vfend	4 months stock by reference to usual PBS demand
Voriconazole	insert: Tablet 200 mg	Oral	Vfend	between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand

84 Schedule 1

Ziprasidone	Omit: Capsule 20 mg (as hydrochloride)	Oral	APO-Ziprasidone	between 1 November 2023 and 31 December 2023— 0 months stock by reference to usual demand
Ziprasidone	Capsule 40 mg (as hydrochloride)	Oral	APO-Ziprasidone	between 1 November 2023 and 31 December 2023— 0 months stock by reference to usual demand
Ziprasidone	Capsule 60 mg (as hydrochloride)	Oral	APO-Ziprasidone	between 1 November 2023 and 31 December 2023— 0 months stock by reference to usual demand
Ziprasidone	Capsule 80 mg (as hydrochloride)	Oral	APO-Ziprasidone	between 1 November 2023 and 31 December 2023— 0 months stock by

reference to usual
demand

Schedule 2—Amendments commencing 1 June 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1

After:

Chloramphenicol	Eye drops 5 mg per mL, 10 mL	Application to the Eye	Chlorsig	4 months stock by reference to usual PBS demand
-----------------	------------------------------	------------------------	----------	-------------------------------------------------

insert:

Chlorpromazine	Injection containing chlorpromazine hydrochloride 50 mg in 2 mL	Injection	Largactil	6 months stock by reference to usual PBS demand
Chlorpromazine	Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL	Oral	Largactil	6 months stock by reference to usual PBS demand
Chlorpromazine	Tablet containing chlorpromazine hydrochloride 100 mg	Oral	Largactil	6 months stock by reference to usual PBS demand

2 Schedule 1

Omit:

Chlorpromazine	Tablet containing chlorpromazine hydrochloride 25 mg	Oral	Largactil	4 months stock by reference to usual PBS demand
----------------	------------------------------------------------------	------	-----------	-------------------------------------------------

substitute:

Chlorpromazine	Tablet containing chlorpromazine hydrochloride 25 mg	Oral	Largactil	6 months stock by reference to usual PBS demand
----------------	------------------------------------------------------	------	-----------	-------------------------------------------------

3 Schedule 1

After:

Paraffin with retinol palmitate	Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinol palmitate, 5 g	Application to the Eye	VitA-POS	between 1 April 2024 and 30 September 2024—0 months stock by reference to usual demand
---------------------------------	-------------------------------------------------------------------------------------------------------------------------------------	------------------------	----------	----------------------------------------------------------------------------------------

insert:

Periciazine	Tablet 10 mg	Oral	Neulactil	6 months stock by reference to usual PBS demand
-------------	--------------	------	-----------	-------------------------------------------------

4 Schedule 1

Omit:					
Periciazine	Tablet 2.5 mg	Oral	Neulactil	4 months stock by reference to usual PBS demand	
substitute:					
Periciazine	Tablet 2.5 mg	Oral	Neulactil	6 months stock by reference to usual PBS demand	